secwatch.observer — SEC 8-K summary
======================================

Issuer:     ARROWHEAD PHARMACEUTICALS, INC. (ARWR)
CIK:        0000879407
Form:       8-K
Filed at:   2025-05-12T23:59:59+00:00
Accession:  0001628280-25-024675
Event type: earnings
Sentiment:  positive
Materiality: 0.85
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Arrowhead Q2 revenue $542.7M on Sarepta deal; plozasiran PDUFA Nov 18, 2025
---------------------------------------------------------------------------

- Q2 revenue of $542.7M (vs $0 prior year) driven by $825M Sarepta licensing deal ($500M cash + $325M equity).
- GAAP diluted EPS $2.75 vs ($1.02) loss YoY; net income $370.4M.
- FDA accepted plozasiran NDA for FCS with PDUFA date Nov 18, 2025; no advisory committee planned.
- CFO Ken Myszkowski retiring May 13, 2025; succeeded by Daniel Apel.
- Cash and investments $1.097B; company funded into 2028 with no near-term equity needs.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/879407/000162828025024675/0001628280-25-024675-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/879407/000162828025024675/arwr-20250512.htm
  HTML page:      https://secwatch.observer/filing/0001628280-25-024675

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer